mastercohort.it

1. Maggiolo F., Maserati R., Castelli F., Pan A., Suter F. for the members of the MASTER group a collaborative network of clinicians and scientists working across Italy in the HIV/AIDS field. Salvage therapy in HIV- positive patients with a previous therapeutic experience with protease inhibitors. AIDS 1999;13:1591-93.

2. Mario Clerici, Elena Seminari , Fredy Suter, Francesco Castelli, Angelo Pan, M. Biasina, Fulvia Colombo, Daria Trabattoni, Franco Maggiolo, Giampiero Carosi and Renato Maserati for the Master Cohort. Different immunologic profiles characterize HIV infection in highly active antiretroviral therapy-treated and antiretroviral-naive patients with undetectable viraemia AIDS 2000, 14:109-116.

3. Giampiero Carosi, Francesco Castelli, Fredy Suter, Franco Maggiolo, Anna Maria Orani, Angelo PanMassimo Andreoni, Gian Marco Vigevani, Renato Maserati, Francesco Mazzotta, Carmine Tinelli, and the MASTER Study Group Antiviral Potency of HAART Regimens and Clinical Success Are Not Strictly Coupled in Real Life Conditions: Evidence from the MASTER-1 Study. HIV Clinical Trials 2001;2(5):399–407.

4. Mario Clerici, Elena Seminari, Franco Maggiolo, Angelo Pan, Marco Migliorino, Daria Trabattoni, Francesco Castelli, Fredy Suter, Maria Luisa Fusi, Lorenzo Minoli, Giampiero Carosi and Renato Maserati for the Master Group Early and late effects of highly active antiretroviral therapy: a 2 year follow-up of antiviral-treated and antiviral-naive chronically HIV-infected patients AIDS 2002, 16:1767–1773.

5. Mazzotta F., Lo Caputo S., Torti C., Tinelli C., Pierotti P., Castelli F., Lazzarin A., Angarano G., Maserati R., Gianotti N., Ladisa N., Quiros-Roldan E., Rinehart A., Carosi G., for the GenPherex Group of the Italian MaSTeR Cohort. Real- vs. virtual-phenotype to guide treatment in heavily pre-treated patients: 48 week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial. Journal of Acquired Immune Deficiency Syndromes 2003, 32: 268-280.

6.  Torti C., Quiros-Roldan E., Keulen W., Scudeller L., Lo Caputo S., Boucher C., Castelli F., Mazzotta F., Pierotti P., Been-Tiktak A.M., Buccoliero G., De Gennaro M., Carosi G., Tinelli C, for the GenPherex Group of the MaSTeR Cohort. Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real- or virtual-phenotype: concordance analysis and correlation with clinical outcome in heavily treated patients. The Journal of Infectious Diseases 2003, 188:194-20.

7. Torti C., Quiros-Roldan E., Scudeller L., Lo Caputo S., Tomasoni L., Castelli F., Poggio A., Delle Foglie P., Sighinolfi L., Mazzotta F., Carosi G., for the GenPheRex Group of the Italian Ma.S.Te.R. Cohort. Characterization of viro-immunological responses in a closely followed cohort of heavily pretreated patients: evidence from the GenPherex study. HIV Medicine 2003, 4: 263-270.

8. Scudeller L., Torti C., Quiros-Roldan E., Patroni A., Lo Caputo S., Moretti F., Mazzotta F., Donati E., Vivarelli E., Carosi G., for the GenPheRex Group of the MASTER Cohort.Amprenavir HIV susceptibility: phenotype-based versus rules-based interpretations. The Journal of Antimicrobial Chemotherapy 2003; 52:776-781.

9. Torti C., Quiros-Roldan E., Regazzi-Bonora M., De Luca A., Lo Caputo S., Di Giambenedetto S., Patroni A., Villani P., Micheli V., Carosi G. Lipid abnormalities in HIV-infected patients are not correlated with lopinavir plasma concentrations. Journal of Acquired Immune Deficiency Syndromes, 2004; 35: 324-325.

10. Torti C., Quiros-Roldan E., Monno L., Patroni A., Saracino A., Angarano G., Tinelli C., Lo Caputo S., Pierotti P., Mazzotta F., Carosi G. for the GenPheRex and PhenGen study groups of the MASTER Cohort. Dideoxynucleoside reverse transcriptase inhibitors HIV-1 resistance: genotypic and phenotypic correlations. Journal of Acquired Immune Deficiency Syndromes 2004; 36: 1104-1107.

11. Torti C., Quiros-Roldan E., Monno L., Patroni A., Saracino A., Angarano G., Tinelli C., Lo Caputo S., Tirelli V., Mazzotta F., Carosi G. for the GenPheRex and PhenGen study groups of the MASTER Cohort. Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients. Journal of Medical Virology 2004; 74: 29-33.

12. Saracino A., Monno L., Lo Caputo S., Torti C., Scudeller L., Ladisa N., Antinori A., Sighinolfi L., Chirianni A., Mazzotta F., Carosi G., Angarano G. Selection of antiretroviral therapy guided by genotypic or phenotypic resistance testing: an open-label, randomized, multicenter study (PhenGen). Journal of Acquired Immune Deficiency Syndromes 2004; 37: 1587-1598.

13. Torti C., Quiros-Roldan E., Tirelli V., Regazzi-Bonora M., Moretti F., Pierotti P., Orani A., Maggi P., Cargnel A., De Luca A., Carosi G. for the RADAR study group of the MASTER Cohort. Lopinavir plasma levels in salvage regimens for a population of heavily treated HIV-1 positive patients. AIDS Patient Care and STDs 2004; 18: 629-634.

14. Massimo Puoti, Barbara Zanini, Gian Paolo Quinzan, Laura Ravasio, Giuseppe Paraninfo, Teresa Santantonio, Adriano Rollo, Stefania Artioli, Franco Maggiolo, Serena Zaltron, MASTER HIV/HCV Co-infection study group, Enzo Raise, Ermenegildo Mignani, Francesco Resta, Gabriella Verucchi, Giuseppe Pastore, Fredy Suter, Giampiero Carosi. A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients. Journal of Hepatology 41 (2004) 312–318.

15. Torti C., Quiros-Roldan E., Regazzi M., De Luca A., Mazzotta F., Antinori A., Ladisa N., Micheli V., Orani A., Patroni A., Villani P., Lo Caputo S., Moretti F., Di Giambenedetto S., Castelnuovo F., Maggi P., Tinelli C., Carosi G., The RADAR-MASTER Study Group. A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug resistance interpretation with or without concentration-controlled intervention: the Resistance And Dosage Adapted Regimens (R.A.D.A.R) study. Clinical Infectious Diseases, 2005; 40: 1828-1836.

16. Torti C., Quiros-Roldan E., Regazzi M., Antinori A., Patroni A., Villani P., Tirelli V., Cologni G., Zinzi D., Lo Caputo S., Perini P., Carosi G, the KARINA-Sisther collaboration Group of the MASTER Cohort. Early virological failure after tenofovir+didanosine+efavirenz combination in HIV-positive patients upon starting antiretroviral therapy. Antiviral Therapy, 2005; 10:505-513.

17. Torti C., Lapadula G., Casari S., Nelson M., Puoti M., Quiros-Roldan E., Bella D., Pastore G., Ladisa N., Minoli L., Sotgiu G., Mazzotta F., Lo Caputo S., Di Perri G., Filice G., Carosi G. Incidence and risk factors for liver enzyme elevation during antiretroviral therapy in HIV/HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. BMC Infectious Diseases, 2005; 5:58.

18. Torti C., Maggiolo F., Patroni A., Suter F., Ladisa N., Paraninfo G., Pierotti P., Orani A., Minoli L., Arici C., Sighinolfi L., Tinelli C., Carosi G. the MASTER Cohort. Exploratory analysis for the evaluation of lopinavir/ritonavir versus efavirenz based HAART regimens in HIV-positive patients naive for antiretrovirals: results from the MASTER Cohort. Journal of Antimicrobial Chemotherapy, 2005; 56: 190-195.

19. Saracino A., Monno L., Scudeller L., Cibelli D.C., Tartaglia A., Punzi G., Torti C., Lo Caputo S., Mazzotta F., Scotto G., Carosi G., Angarano G. Impact of previously unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors. Journal of Medical Virology, 2006; 78: 9-17.

20. Torti C., Lapadula G., Puoti M., Casari S., Uccelli M.C., Cristini G., Bella D., Pastore G., Ladisa N., Minoli L., Sotgiu G., Lo Caputo S., Bonora S., Carosi G. The influence of genotype 3 hepatitis C co-infection on liver enzyme elevation after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER cohort. Journal of Acquired Immune Deficiency Syndromes, 2006; 41: 180-185.

21. Torti C., Uccelli M.C., Quiros-Roldan E., Tirelli V., Regazzi M., Pierotti P., Tinelli C., De Luca A., Patroni A., Carosi G., The RADAR-MASTER Study Group. Prediction of early and confirmed virological response by a genotypic inhibitory quotient for lopinavir in patients with limited exposure to previous protease inhibitors. Journal of Clinical Virology, 2006; 35: 414-419.

22. Lapadula G., Torti C., Paraninfo G., Castelnuovo F., Uccelli M.C., Costarelli S., Ladisa N., Maserati R., Di Pietro M., Puoti M., Carosi G., EPOKA-a study group of the MASTER Cohort.Influence of hepatitis C genotype on lipid elevations in HIV-positive patients during highly active antiretroviral therapy. Antiviral Therapy, 2006; 11: 521-527.

23. Maggiolo F., Ripamonti D., Torti C., Arici C., Antinori A., Quiros-Roldan E., Minoli L., Sighinolfi L., Nasta P., Suter F. for the MASTER data-base Cohort. Effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens. Antiviral Therapy, 2006; 11: 923-929.

24. Torti C., Lapadula G., Uccelli M.C., Gargiulo F., Quiros-Roldan E., Regazzi M., Ladisa N., Micheli V., Orani A., Patroni A., Lo Caputo S., Moretti F., Tirelli V., Di Giambenedetto S., Cologni G., Costarelli S., Manca N., Carosi G. Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patients. International Journal of Antimicrobial Agents, 2007; 29: 185-190.

25. Larder B., Wang D., Revell A., Montaner J., Harrigan R., De Wolf F., Lange J., Wegner S., Ruiz L., Pérez-Elías M.J., Emery S., Gatell J., D'Arminio Monforte A., Torti C., Zazzi M., Lane C.The development of artificial neural networks to predict virological response to combination HIV therapy. Antiviral Therapy, 2007; 12: 15-24.

26. Quiros-Roldan E., Torti C., Lapadula G., Ladisa N., Micheli V., Patroni A., Villani P., Lo Caputo S., Tirelli V., Uccelli M.C., Di Giambenedetto S., Castelnuovo F., Tinelli C., Carosi G.Adherence and plasma drug concentrations are independently correlated with confirmed virological response to salvage HAART. AIDS Patient Care and STDs, 2007; 21: 92-99.

27. Torti C., Lapadula G., Barreiro P., Soriano V., Mandalia S., De Silvestri A., Suter F., Maggiolo F., Antinori A., Antonucci F., Maserati R., El Hamad I., Pierotti P., Sighinolfi L., Migliorino G., Ladisa N., Carosi G. on behalf of the Italian MASTER Cohort.CD4+ T-cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in presence of sustained undetectable HIV plasma viral load. The Journal of Antimicrobial Chemotherapy 2007; 59:1141-1147.

28. Torti C., Lapadula G., Tinelli C., De Silvestri A., Maggiolo F., Casari S., Suter F., Minoli L., Pezzoli C., Di Pietro M., Migliorino G., Quiros-Roldan E., Ladisa N., Sighinolfi L., Gatti F., Carosi G. for the Italian MASTER Cohort. Predictors of AIDS defining events and deaths among advanced naïve patients after HAART. HIV Clinical Trials 2007; 8: 112-120.

29. Lapadula G., Torti C., Maggiolo F., Casari S., Suter F., Minoli L., Pezzoli C., Di Pietro M., Migliorino G., Quiros-Roldan E., Ladisa N., Sighinolfi L., Costarelli S, Carosi G. for the Italian MASTER Cohort. Predictors of clinical progression among HIV-1 positive patients starting HAART with CD4+ T-cell count ≥200/mm3. Antiviral Ther 2007; 12: 941-947.

30. Sighinolfi L., Torti C., Zeni C., Ghinelli F., Suter F., Maggiolo F., Antinori A., Antonucci F., Castelnuovo F., Ladisa N., Migliorino M., Novati S., De Luca A., Lo Caputo S., Paraninfo G., Tinelli C., Carosi G. Evolution of antiretroviral prescription and response over a period of 8 years: an Italian multicentre observational prospective cohort study. Infection. 2008 Jun;36(3):244-9.

31. Torti C., Quiros-Roldan E., Cologni G., Nichelatti M., Tirelli V., Pinti M., Nasi M., Cossarizza A., Lapadula G., Costarelli S., Manca N., Gargiulo F., Magoni M., Carosi G. Plasma viral load and proviral DNA decreases after two standard antiretroviral regimens in HIV-positive patients naive to antiretrovirals. Curr HIV Res. 2008 Jan;6(1):43-8.

32. Torti C., Lapadula G., Antinori A., Quirino T., Maserati R., Castelnuovo F., Maggiolo F., De Luca A., Paraninfo G., Antonucci F., Migliorino G., Lazzarin A., Di Perri G., Rizzardini G., Esposito R., Carosi G. Hyperbilirubinemia after atazanavir containing regimens and relationship with flares of hepatic tranasminases in a large population of HIV infected subjects: joined analysis of the Italian Atazanavir Expanded Access Program and the Italian MASTER Cohort databases. Infection. 2009 Jun;37(3):244-9.

33. Müller V, Maggiolo F, Suter F, Ladisa N, De Luca A, Antinori A, Sighinolfi L, Quiros-Roldan E, Carosi G, Torti C. Increasing clinical virulence in two decades of the Italian HIV epidemic. PLoS Pathog. 2009 May;5(5):e1000454.

34. Seminari E, Tinelli C, Ravasi G, Ripamonti D, Ladisa N, Marino N, Sighinolfi L, Mondello P, Migliorino M, Carosi G, Maserati R; MASTER Cohort. Hepatitis C Infection on Immune Recovery in HIV-Positive Patients on Successful HAART: The Role of Genotype 3. Curr HIV Res. 2010 Feb 18.